跳至主要内容
临床试验/NCT05183308
NCT05183308已完成不适用

The Effect of Combined Drug Therapy in Lateral Fragility Fractures of the Femur:a Clinical Study

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2019年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
1
主要终点
Change in Visual Analogic Scale

研究概览

简要总结

It was conducted a prospective study with a series of 50 patients treated by intramedullary nail using Clodronic acid and Vitamin D (study group including 25 patients) and patients with the same fractures treated with Vitamin D alone (control group including 25 patients).

One independent observer performed clinical, biochemical and functional evaluations at T0 (1st day post-surgery) and at T1 (12 months later) Biochemical markers (serum calcium level, serum phosphate level, PTH (parathormone), Vitamin D, serum C-terminal telopeptide), VAS (Visual Analogic Scale) and HHS (Harris Hip Score) score, and femur densitometric views were administered at each evaluation.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
60 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • femur fractures type 31-A1, A2, (Muller ME, Nazarian S, Kock P et al.);
  • age 60 - 85 years;
  • co-operative patients;
  • Body Mass Index (BMI) < 30 Kg/m²;
  • patients treated by intramedullary nailing surgery (PFNA Synthes®);
  • patients with osteoporosis disease if T-Score< -2,5;

排除标准

  • patients with heart, kidney, neurological diseases;
  • patients with metabolic and systemic disease (rheumatoid arthritis, diabetes mellitus);
  • previous surgery or severe osteoarthritis of lower limbs;
  • specific drugs treatments such as anticoagulants or psychiatric drugs.

研究组 & 干预措施

patients treated with Vitamin D and Clodronic Acid

干预措施: Clodronic Acid (Drug)

结局指标

主要结局

Change in Visual Analogic Scale

时间窗: Day 1; Month 12 (after surgey)

The Hip Pain was quantified using the Visual Analogic Scale ranging between 0 (no pain) and 10 points (worst imaginable pain).

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验